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prognostic biomarker and provide an attractive 
therapeutic target for TNBC.
B38	 Distinct	functions	for	tumor-associated	
fibroblasts	in	melanoma	growth.	LinLi Zhou, Kun 
Yang, Makoto M. Taketo, de Crombrugghe B, Yuhang 
Zhang. Division of Pharmaceutical Sciences, College 
of Pharmacy, University of Cincinnati, Cincinnati, OH, 
USA.
One origin of Tumor-associated fibroblasts (TAFs) 
is considered to be skin resident fibroblasts. 
Nevertheless, how local fibroblasts are stimulated 
to enter a continuous state of irreversible activation 
and establish an environment conductive for 
tumor development remains poorly understood. 
To address this, we inducibly deleted b-catenin in 
stromal fibroblasts in order to identify the molecular 
basis underlying the tumor-supportive functions 
of TAFs during the development of melanoma. 
Nuclear b-catenin was detected in TAFs inside 
and surrounding melanocytic neoplasm. Following 
constitutive expression of b-catenin in dermal 
fibroblasts, mouse rapidly developed skin abnormality 
and dermal fibrosis, including skin thickening, 
accumulation of collagen fibers and production 
of a large amount of growth factors, cytokine and 
extracellular matrix proteins, including EGF, FN1 and 
TNC, etc. By contrast, specific deletion of b-catenin in 
fibroblasts significantly decreased generation of those 
chemical factors as well as alleviated dermal fibrosis. 
Furthermore, Loss of b-catenin significantly blocked 
fibroblast growth and migration in vitro, and failed 
to support melanoma cells to grow. We first asked 
whether local dermal fibroblast support or inhibit 
melanoma growth at tumor initiation stage by grafting 
B16F10 melanoma cells to immunodeficient nude 
mice. Melanoma tumor grew bigger when β-catenin 
is ablated in fibroblasts than those with control wild 
type fibroblasts. This finding confirms that stromal 
fibroblasts in the vicinity of tumor cells initially repress 
malignant growth, and the loss of b-catenin would 
deprive their ability to counteract tumor development. 
However, when b-catenin was ablated in TAFs later 
after tumor was formed, melanoma development 
was significantly delayed, exhibiting a different effect 
on tumor development. Further studies showed that 
cell cycle progression and pRB signaling pathway 
are affected by secreted chemical factors from TAFs 
that significantly blocked melanoma cell growth. 
Thus, targeting Wnt/b-catenin signaling pathway in 
TAFs has the potential to activate pRB signaling and 
blocking cell cycle in melanoma cells, representing a 
novel therapeutic approach to conquer melanoma.
B39	 Cooperation	of	epithelial-mesenchymal	
transition	and	cellular	stress	response	in	
promoting	metastasis.	Yu-xiong Feng1, Dexter 
X. Jin1,2, Piyush B. Gupta1-5. 1Whitehead Institute 
for Biomedical Research, Cambridge, MA, USA, 2 
Department of Biology, Massachusetts Institute of 
Technology, Cambridge, MA, USA, 3 Koch Institute for 
Integrative Cancer Research, Cambridge, MA, USA, 
4 Harvard Stem Cell Institute, Cambridge, MA, USA, 
5Broad Institute, Cambridge, MA, USA.
Epithelial-to-mesenchymal transition (EMT) plays 
a central role in cancer progression. Through an 
EMT, cancer cells acquire a spectrum of malignant 
properties, including invasiveness, chemo-resistance 
and stem-like traits. With an aim to effectively 
target EMT-cancer cells, we previously performed 
a high throughput chemical and RNAi screen, and 
discovered that EMT-cancer cells are hypersensitive 
to perturbations of endoplasmic reticulum (ER) 
function, which represents a specific vulnerability 
of cancer cells that have undergone this cell-state 
transition. This increased sensitivity to ER stress 
of EMT-cancer cells is largely due to the increased 
synthesis and secretion of extracellular matrix (ECM) 
proteins. In line with this fundamental change, 
EMT-cancer cells constitutively activate the PERK-
ATF4 branch of the unfolded protein response 
(UPR) pathway. Surprisingly, we found that the 
PERK pathway, in addition to mediating ER stress 
response, is required for acquisition of malignant 
features of the EMT-cancer cells. Mechanistically, 
the PERK-ATF4 signaling cooperates with the 
EMT transcription factors to induce a CREB family 
transcription factor, which is critical for maintaining 
the EMT-specific secretome. Inhibition of this factor 
markedly suppresses EMT-driven metastasis, while 
overexpressing this protein endows non-EMT cancer 
cells an increased metastatic capacity. In summary, 
we discovered a non-canonical role of the PERK-
ATF4 stress response pathway in driving metastasis.
B40	 RhoE/ROCK	signaling	modulates	
chemoresistance	in	HCC	through	IL6/JAK2/STAT3	
pathways.	W Ma, KM Sze, LK Chan, JM Lee, VC 
Cheung, TKW Lee, CCL Wong, IOL Ng. Department 
of Pathology, Li Ka Shing Faculty of Medicine and 
State Key Laboratory for Liver Research, The 
University of Hong Kong, Hong Kong.
Liver cancer (hepatocellular carcinoma, HCC) is 
a major malignancy worldwide and the second 
commonest fatal cancer in Southeast Asia and 
China including Hong Kong, due to the high 
prevalence of hepatitis B viral infection. HCC is highly 
chemoresistant, limiting treatment options to patients. 
There is an urgent need to delineate the underlying 
molecular mechanism of HCC chemoresistance 
so as to identify novel therapeutic targets for this 
aggressive cancer. Deregulation of Rho GTPase 
pathway is demonstrated to play important roles 
in HCC tumorigenesis. RhoE/Rnd3 belongs to the 
Rnd subfamily of the Rho GTPase which lacks the 
intrinsic GTPase activity. In our previous study, we 
Poster Session B
100 American Association for Cancer Research
have shown that RhoE is frequently downregulated in 
human HCCs and acts as a metastasis suppressor, 
whereas ROCK2 is upregulated in human HCCs. In 
this study, we aimed to investigate whether RhoE is 
also involved in the regulation of chemoresistance 
in HCC. Using short-hairpin RNA and a lentiviral 
approach, we knocked down RhoE in BEL-7402 
and MHCC-97L HCC cells. RhoE knockdown cells 
displayed increased resistance to chemotherapeutic 
drugs, cisplatin and doxorubicin. Knockdown of 
RhoE also reduced cisplatin-induced apoptosis. 
On the other hand, addition of ROCK inhibitor, 
Y27632, sensitized the HCC cells to these two 
drugs. We further demonstrated that knockdown 
of RhoE enhanced chemoresistance in an in 
vivo subcutaneous injection model in nude mice; 
treatment with cisplatin significantly suppressed the 
tumor growth of the non-target control group while 
it had no effect in the RhoE knockdown group. In 
addition, treatment with ROCK inhibitor Y27632 
sensitized HCC cells to cisplatin treatment in vivo; 
co-treatment of cisplatin and Y27632 suppressed 
subcutaneous tumor growth of BEL-7402 to a greater 
extent than cisplatin alone.
The downstream molecular targets of Rho/ROCK that 
regulates cell survival and chemoresistance remain 
largely unknown. Therefore we also investigated 
the molecular pathway which Rho/ROCK signaling 
might act on in mediating its pro-survival effect. 
IL6/JAK/STAT3 pathway has been shown to be 
important in regulating HCC chemoresistance, and 
previous studies have also suggested that Rho/
ROCK pathway may interfere with the IL6/JAK/
STAT3 pathway. We tested whether RhoE/ROCK 
modulated chemoresistance through IL6/JAK/
STAT3 in HCC. Addition of Y27632 suppressed IL6 
mRNA expression and IL6 secretion in BEL-7402 
and SMMC-7721 HCC cells. We also observed 
up-regulation of JAK2 and STAT3 phosphorylation 
levels in the transient RhoE knockdown BEL-7402 
cells using Western blot analysis. On the other 
hand, knockdown of ROCK2 and addition of Y27632 
suppressed the phosphorylation of both JAK2 and 
STAT3. Dual luciferase reporter assay showed that 
the transcription activity of STAT3 was reduced upon 
Y27632 treatment in BEL-7402 and SMMC-7721. 
Immunohistochemical staining of the phospho-STAT3 
in the subcutaneous tumors from nude mice treated 
with and without cisplatin and Y27632 confirmed 
that treatment of Y27632 also repressed STAT3 
phosphorylation in vivo.
To conclude, downregulation of RhoE in HCC 
enhanced chemoresistance both in vitro and in vivo 
via upregulating the activities of ROCK. We identified 
the IL6/JAK2/STAT3 pathway to be a novel target of 
ROCK in promoting cell survival. Targeting the Rho/
ROCK pathway may be a potential therapeutic in 
enhancing HCC treatment.
B41	 GPR56	inhibits	melanoma	progression	by	
internalizing	TG2	in	extracellular	matrix.	Liquan 
Yang1,2, Nancy Corson1, Lei Xu1. 1 Department 
of Biomedical Genetics, University of Rochester 
Medical Center, Rochester, NY, USA, 2Current 
Address:  Winship Cancer Institute and Department 
of Neurosurgery, Emory University, Atlanta, GA, USA.
A critical component in tumor microenvironment 
is extracellular matrix (ECM).  ECM is assembled 
by large polypeptides in the extracellular space.  It 
forms a scaffold to support tissue structure and 
development and also serves as a repertoire of 
growth factors to promote cell growth.  ECM proteins 
also directly bind to and signal through adhesion 
receptors, such as integrins, to regulate cell survival, 
proliferation, and migration.  Excessive accumulation 
and crosslinking of ECM is a hallmark of cancer and 
has been shown to promote cancer progression by 
activating integrins and Rho GTPases.  Its removal 
should have therapeutic benefits for cancer patients, 
but this potential has not been actively pursued.  We 
recently discovered that a novel adhesion receptor, 
GPR56, inhibits melanoma growth and metastasis 
via removing its ligand, TG2, from ECM.  GPR56 
belongs to the family of adhesion G protein-coupled 
receptors (GPCRs), a group of important but poorly 
understood receptors.  It was one of the down-
regulated genes in the highly metastatic derivatives 
compared with the poorly metastatic melanoma 
parental line.  Over-expression of GPR56 led to 
inhibition on melanoma growth and metastasis, and 
its knockdowns led to their enhancement.  Results 
from later studies suggested that this inhibitory 
effect of GPR56 might apply to both BI-sensitive 
and BI-resistant melanomas, and probably occurs 
during the expansion of micrometastases into 
overt macrometastases.  Our earlier work also 
discovered that TG2, a crosslinking enzyme in the 
extracellular matrix (ECM), binds to the N-terminus 
of GPR56, linking GPR56 with ECM remodeling 
during melanoma growth and metastasis.  Indeed, 
studies using the immunodeficient Tg2-/- mice showed 
that TG2 itself promotes melanoma metastasis 
but GPR56 antagonizes it.  Biochemical analyses 
were performed to understand this antagonism and 
showed that GPR56 removes TG2 from melanoma 
cell surface via receptor-mediated endocytosis, 
leading to impaired ECM deposition and adhesion.  
These results provided the first line of evidence that 
ECM removal may be feasible for cancer treatment, 
and GPR56 may serve as a target for this ECM-
based therapy in treating metastatic melanoma.  
B42	 MET	suppresses	epithelial	VEGFR2	
via	intracrine	VEGF-induced	ER-associated	
degradation.	Tom T. Chen1, Ellen Filvaroff1*, Jing 
Peng2, Scot Marsters1, Adrian Jubb3, Hartmut 
Koeppen3, Mark Merchant2, and Avi Ashkenazi1**. 
Genentech.
Hepatocyte growth factor (HGF) and vascular 
endothelial growth factor (VEGF) drive cancer 
through their respective receptors, MET and 
